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There is growing evidence regarding the risk of cervical arterial dissection and i tracerebral haemorrhage 
immediately following alemtuzumab infusion, for relapsing remitting multiple sclerosis (MS). Durand-Dubief et 
al. reported a case of multiple cervical arterial dissections days after treatment with alemtuzumab.1 Five cases of 
intracerebral haemorrhage were recently reported by Azevedo et al.2 In November 2018, this concern prompted 
the United States Food and Drug Administration (FDA) to add the risk of stroke within three days of 
administration to the boxed warning on the drug’s label.3 The FDA commented on the possible causative role of 
cytokine release syndrome, but decided there was insufficient evidence. The Europ an Medicines Agency 
(EMA) have recently launched a safety review, placed interim restrictions on the prescription of alemtuzumab, 
and focussed on blood pressure, advising: “For patients being treated with Lemtrada®, vital signs should be 
monitored before and during the intravenous infusion.”4 Azevedo et al. suggested that hypertension, or acute 
fluctuations in blood pressure, may be responsible for acute haemorrhagic strokes and proposed four criteria that 
should prompt admission for inpatient observation with strict blood pressure control. Either a 20% or 20mmHg 
increase in the mean daily systolic blood pressure (SBP), or a one-off value that exceeds the patients’ baseline 
SBP by the same extent. Chinea et al. subsequently reported their prospective obser ational safety study of 
alemtuzumab administration and found that 39% of their cohort had a SBP ≥160 mmHg at least once during 
treatment, and only half of this group had a pre-existing diagnosis of hypertension.5 
We audited 83 consecutive patients receiving their first course of alemtuzumab therapy for MS from our three 
MS centres. Blood pressure was recorded prior to infusion and at 30-minute intervals for up to four hours post 
infusion. The cohort was 73% female; had a mean age of 36; a median EDSS of 3.0, and 27% received 
alemtuzumab as first line therapy. Five patients had a pre-existing diagnosis of hypertension, two were obese, 
two were current smokers, one was an ex-smoker and one had type two diabetes mellitus. Pr -medication given 
prior to each infusion consisted of methylprednisolone 500-1000mg, acetaminophen 1000mg, and 
diphenhydramine 50mg or cetirizine 10mg.  
While there was no significant change in mean or peak SBP or diastolic blood pressure over the five infusion 
days (≤3mmHg), Azevedo’s proposed criteria were met by 59% of the cohort at least once across all five days 
of treatment (table 1). There was no routine monitoring for evidence of cytokine release syndrome. In our 
cohort, there was one case of carotid artery dissection, occurring after the thi d day of alemtuzumab infusion in 
a female patient aged 25 years old. Just as with Durand-Dubief’s case, she had no history of a connective tissue 
disorder, trauma, or a recent infection.  This patient met only one of Azevedo’s proposed criteria; on the day the 
dissection occurred the patient’s SBP had a one-off value in excess of 20mmHg of that day’s baseline.  
Based on this data, we believe that the clinical observations suggested by Azevedo et al. and the EMA lack 
clinical utility in identifying people at risk of cervicocephalic arterial dissection or cerebrovascular events 
during treatment with alemtuzumab. The proposed criteria lack specificity due to the variability of routine 
clinical SBP recordings and the rarity of adverse ev nts. We believe further safety studies are needed to help 
mitigate the risks of therapy, exploring the value of additional monitoring for evidence of cytokine release 
syndrome, not just blood pressure monitoring. Monitoring for cytokine release syndrome might include a 
combination of clinical observation and blood testing for markers of cytokine release such as D-dimers, 
prothrombin time, TNF-α, IFN-γ and IL -6.    
Table 1 
Proposed Criteria Patients meeting criteria (%) 
Mean daily SBP >20% pre-treatment baseline 11 (13) 
Mean daily SBP >20mmHg pre-treatment baseline 13 (16) 
Daily peak SBP >20% daily baseline 33 (40) 
Daily peak SBP >20mmHg daily baseline 45 (54) 
Meeting any of the criteria during treatment 49 (59) 
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